Drugs / Ebastine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06480110 | Jun 2024 → Dec 2026 expected | castration-resistant prostate carcinoma | Rigshospitalet, Denmark | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05815602 | Mar 2023 → Oct 2027 expected | irritable bowel syndrome | Guy Boeckxstaens | Active not recruiting | No outcome recorded |
| Comparator or background therapy6 trials | ||||||
| Phase 2/3 | NCT07114055 Comparator | Aug 2025 → Jul 2026 overdue | irritable bowel syndrome | Md. Hazrat Ali | Recruiting | No outcome recorded |
| Phase 4 | NCT01908465 Comparator | Nov 2013 → Nov 2022 | irritable bowel syndrome | KU Leuven | Completed | No outcome recorded |
| Phase 4 | NCT01940393 Comparator | Aug → Dec 2013 | urticaria | Grupo de Alergología Clínica y Experimental | Completed | No outcome recorded |
| Phase 4 | NCT01144832 Comparator | Oct 2009 → May 2012 | irritable bowel syndrome | KU Leuven | Completed | No outcome recorded |
| — | NCT07114107 Background | Aug 2025 → Mar 2026 overdue | allergic asthma, allergic rhinitis | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| — | NCT02065440 Comparator | Sep 2011 → Feb 2014 | — | Seoul National University Hospital | Unknown | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ebastine | “Rhinoebastel(ebastine 10mg/pseudoephedrine 120mg) 1 cap/day for 1 week unless progression or unacceptable toxicity develops.” NCT02065440 ↗7“antihistamines(Ebastine 10 mg once daily for 2 weeks)” NCT07114107 ↗ |
| Known as | Ebastina | ChEMBL registry synonym — accepted as the source's own label CHEMBL305660 ↗ |
| Known as | Kestine (Ebastine) | “Kestine (Ebastine)” NCT06480110 ↗ |
| Known as | LAS W-090 | ChEMBL registry synonym — accepted as the source's own label CHEMBL305660 ↗ |
| Known as | RP 64305 | ChEMBL registry synonym — accepted as the source's own label CHEMBL305660 ↗ |
| Action | Inhibit | “Ebastine, an antagonist of HRH1, reduced visceral hypersensitivity, symptoms, and abdominal pain in patients with IBS.” PMID 26752109 ↗ Jan 2016 |
| Modality | Small molecule | — CHEMBL305660 ↗ |
| Route | Oral | “Patients received a daily oral dose of cetirizine, fexofenadine, bilastine, desloratadine, or ebastine over 8 weeks.” PMID 27326985 ↗ 2016 |
| Target | HRH1 | “Ebastine, an antagonist of HRH1, reduced visceral hypersensitivity, symptoms, and abdominal pain in patients with IBS.” PMID 26752109 ↗ Jan 2016 |